{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:51:22Z","timestamp":1760028682396,"version":"3.37.3"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2020,3,31]],"date-time":"2020-03-31T00:00:00Z","timestamp":1585612800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,3,31]],"date-time":"2020-03-31T00:00:00Z","timestamp":1585612800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1007\/s00392-020-01635-8","type":"journal-article","created":{"date-parts":[[2020,3,31]],"date-time":"2020-03-31T16:03:47Z","timestamp":1585670627000},"page":"1374-1380","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Effect of concomitant antiplatelet agents on clinical outcomes in the edoxaban vs warfarin in subjects undergoing cardioversion of atrial fibrillation (ENSURE-AF) randomized trial"],"prefix":"10.1007","volume":"109","author":[{"given":"Andreas","family":"Goette","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose L.","family":"Merino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raffaele","family":"De Caterina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kurt","family":"Huber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hein","family":"Heidbuchel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory Y. H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,3,31]]},"reference":[{"key":"1635_CR1","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","volume":"369","author":"RP Giugliano","year":"2013","unstructured":"Giugliano RP, Ruff CT, Braunwald E, Murphy SA et al (2013) Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369:2093\u20132104. https:\/\/doi.org\/10.1056\/NEJMoa1310907","journal-title":"N Engl J Med"},{"key":"1635_CR2","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.115.002587","author":"H Xu","year":"2016","unstructured":"Xu H, Ruff CT, Giugliano RP, Murphy SA et al (2016) Concomitant use of single antiplatelet therapy with edoxaban or warfarin in patients with atrial fibrillation: analysis from the ENGAGE AF-TIMI48 trial. J Am Heart Assoc. https:\/\/doi.org\/10.1161\/JAHA.115.002587","journal-title":"J Am Heart Assoc"},{"key":"1635_CR3","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1016\/S0140-6736(16)31474-X","volume":"388","author":"A Goette","year":"2016","unstructured":"Goette A, Merino JL, Ezekowitz MD, Zamoryakhin D et al (2016) Edoxaban versus enoxaparin\u2013warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial. Lancet 388:1995\u20132003. https:\/\/doi.org\/10.1016\/S0140-6736(16)31474-X","journal-title":"Lancet"},{"key":"1635_CR4","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1093\/europace\/euy141","volume":"20","author":"A Goette","year":"2018","unstructured":"Goette A, Kwong WJ, Ezekowitz MD, Banach M et al (2018) Edoxaban therapy increases treatment satisfaction and reduces utilization of healthcare resources: an analysis from the EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of atrial fibrillation (ENSURE-AF) study. Europace 20:1936\u20131943. https:\/\/doi.org\/10.1093\/europace\/euy141","journal-title":"Europace"},{"key":"1635_CR5","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.ijcard.2010.09.004","volume":"154","author":"A Goette","year":"2012","unstructured":"Goette A, Hammwohner M, Bukowska A, Scalera F et al (2012) The impact of rapid atrial pacing on ADMA and endothelial NOS. Int J Cardiol 154:141\u2013146. https:\/\/doi.org\/10.1016\/j.ijcard.2010.09.004","journal-title":"Int J Cardiol"},{"key":"1635_CR6","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1111\/j.1540-8159.2000.tb07041.x","volume":"23","author":"A Goette","year":"2000","unstructured":"Goette A, Ittenson A, Hoffmanns P, Reek S et al (2000) Increased expression of P-selectin in patients with chronic atrial fibrillation. Pacing Clin Electrophysiol 23:1872\u20131875","journal-title":"Pacing Clin Electrophysiol"},{"key":"1635_CR7","first-page":"581","volume":"232","author":"M Hammwohner","year":"2007","unstructured":"Hammwohner M, Ittenson A, Dierkes J, Bukowska A et al (2007) Platelet expression of CD40\/CD40 ligand and its relation to inflammatory markers and adhesion molecules in patients with atrial fibrillation. Exp Biol Med (Maywood) 232:581\u2013589","journal-title":"Exp Biol Med (Maywood)"},{"key":"1635_CR8","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1093\/europace\/euw295","volume":"18","author":"P Kirchhof","year":"2016","unstructured":"Kirchhof P, Benussi S, Kotecha D, Ahlsson A et al (2016) 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace 18:1609\u20131678. https:\/\/doi.org\/10.1093\/europace\/euw295","journal-title":"Europace"},{"key":"1635_CR9","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1093\/eurheartj\/ehy394","volume":"40","author":"FJ Neumann","year":"2019","unstructured":"Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F et al (2019) 2018 ESC\/EACTS Guidelines on myocardial revascularization. Eur Heart J 40:87\u2013165. https:\/\/doi.org\/10.1093\/eurheartj\/ehy394","journal-title":"Eur Heart J"},{"key":"1635_CR10","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.ahj.2015.02.009","volume":"169","author":"GY Lip","year":"2015","unstructured":"Lip GY, Merino J, Ezekowitz M, Ellenbogen K et al (2015) A prospective evaluation of edoxaban compared to warfarin in subjects undergoing cardioversion of atrial fibrillation: the EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) study. Am Heart J 169:597\u2013604. https:\/\/doi.org\/10.1016\/j.ahj.2015.02.009","journal-title":"Am Heart J"},{"key":"1635_CR11","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.ijcard.2018.06.098","volume":"270","author":"G Patti","year":"2018","unstructured":"Patti G, Pecen L, Lucerna M, Huber K et al (2018) Outcomes of anticoagulated patients with atrial fibrillation treated with or without antiplatelet therapy: a pooled analysis from the PREFER in AF and PREFER in AF PROLONGATON registries. Int J Cardiol 270:160\u2013166. https:\/\/doi.org\/10.1016\/j.ijcard.2018.06.098","journal-title":"Int J Cardiol"},{"key":"1635_CR12","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1161\/CIRCULATIONAHA.112.115386","volume":"127","author":"AL Dans","year":"2013","unstructured":"Dans AL, Connolly SJ, Wallentin L, Yang S et al (2013) Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. Circulation 127:634\u2013640. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.112.115386","journal-title":"Circulation"},{"key":"1635_CR13","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1161\/CIRCULATIONAHA.113.004834","volume":"129","author":"M Lamberts","year":"2014","unstructured":"Lamberts M, Gislason GH, Lip GY, Lassen JF et al (2014) Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study. Circulation 129:1577\u20131585. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.113.004834","journal-title":"Circulation"},{"key":"1635_CR14","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1093\/eurheartj\/eht445","volume":"35","author":"JH Alexander","year":"2014","unstructured":"Alexander JH, Lopes RD, Thomas L, Alings M et al (2014) Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J 35:224\u2013232. https:\/\/doi.org\/10.1093\/eurheartj\/eht445","journal-title":"Eur Heart J"},{"key":"1635_CR15","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1001\/archinte.167.2.117","volume":"167","author":"F Dentali","year":"2007","unstructured":"Dentali F, Douketis JD, Lim W, Crowther M (2007) Combined aspirin-oral anticoagulant therapy compared with oral anticoagulant therapy alone among patients at risk for cardiovascular disease: a meta-analysis of randomized trials. Arch Intern Med 167:117\u2013124. https:\/\/doi.org\/10.1001\/archinte.167.2.117","journal-title":"Arch Intern Med"},{"key":"1635_CR16","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1093\/eurheartj\/eht428","volume":"35","author":"KW Mahaffey","year":"2014","unstructured":"Mahaffey KW, Stevens SR, White HD, Nessel CC et al (2014) Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial. Eur Heart J 35:233\u2013241. https:\/\/doi.org\/10.1093\/eurheartj\/eht428","journal-title":"Eur Heart J"},{"key":"1635_CR17","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.amjmed.2018.10.008","volume":"132","author":"A Douros","year":"2019","unstructured":"Douros A, Renoux C, Yin H, Filion KB et al (2019) Concomitant use of direct oral anticoagulants with antiplatelet agents and the risk of major bleeding in patients with nonvalvular atrial fibrillation. Am J Med 132:191\u2013199. https:\/\/doi.org\/10.1016\/j.amjmed.2018.10.008","journal-title":"Am J Med"},{"key":"1635_CR18","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euz033","author":"DA Lane","year":"2019","unstructured":"Lane DA, Dagres N, Dan GA, Garcia Seara J et al (2019) Antithrombotic treatment in patients with atrial fibrillation and acute coronary syndromes: results of the European Heart Rhythm Association survey. Europace. https:\/\/doi.org\/10.1093\/europace\/euz033","journal-title":"Europace"},{"key":"1635_CR19","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.ahj.2017.10.009","volume":"196","author":"P Vranckx","year":"2018","unstructured":"Vranckx P, Lewalter T, Valgimigli M, Tijssen JG et al (2018) Evaluation of the safety and efficacy of an edoxaban-based antithrombotic regimen in patients with atrial fibrillation following successful percutaneous coronary intervention (PCI) with stent placement: Rationale and design of the ENTRUST-AF PCI trial. Am Heart J 196:105\u2013112. https:\/\/doi.org\/10.1016\/j.ahj.2017.10.009","journal-title":"Am Heart J"},{"key":"1635_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31872-0","author":"P Vranckx","year":"2019","unstructured":"Vranckx P, Valgimigli M, Eckardt L, Tijssen J et al (2019) Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. Lancet. https:\/\/doi.org\/10.1016\/S0140-6736(19)31872-0","journal-title":"Lancet"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-020-01635-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00392-020-01635-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-020-01635-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,30]],"date-time":"2021-03-30T23:29:23Z","timestamp":1617146963000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00392-020-01635-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,31]]},"references-count":20,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["1635"],"URL":"https:\/\/doi.org\/10.1007\/s00392-020-01635-8","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"type":"print","value":"1861-0684"},{"type":"electronic","value":"1861-0692"}],"subject":[],"published":{"date-parts":[[2020,3,31]]},"assertion":[{"value":"8 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Andreas Goette, MD, has served as a consultant for Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, and Pfizer; and a speaker for AstraZeneca, Bayer, Berlin-Chemie, Bristol-Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo, Medtronic, Pfizer, and Sanofi-Aventis. Jose L. Merino, MD, has served on the Speakers Bureau for Cardiome, Daiichi Sankyo, Medtronic, and St. Jude Medical; and has served as a consultant for Bayer, Biotronik, Boston Scientific, Bristol-Myers Squibb, Cardiome, Daiichi Sankyo, LivaNova, Medtronic, Pfizer, Sanofi, and St. Jude Medical. Raffaele De Caterina, MD, has received research grants from Pfizer, Daiichi Sankyo, Novartis, Merck Sharp, and Dohme; and has received honoraria from Sanofi, Boehringer-Ingelheim, Bayer, Bristol-Myers Squibb, Pfizer, and Portola. Kurt Huber, MD, has received lecture fees from Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, and Pfizer. Hein Heidbuchel, MD, has served as a consultant or speaker for Boehringer-Ingelheim, Bayer, Bristol-Myers Squibb, Cardiome, Daiichi-Sankyo, Pfizer, and St. Jude Medical. James Jin, PhD, is an employee of Daiichi Sankyo Pharma Development. Gregory Y.H. Lip, MD, has served as a consultant for Bayer\/Janssen, Bristol-Myers Squibb\/Pfizer, Boehringer Ingelheim, Daiichi Sankyo, Medtronic, Novartis, and Verseon; and a speaker for Bayer, Bristol-Myers Squibb\/Pfizer, Boehringer Ingelheim, Daiichi Sankyo, and Medtronic. No fees were directly received personally.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}